MedPath

MSI Methylation Sciences Inc

🇨🇦Canada
Ownership
-
Employees
-
Market Cap
-
Website

Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine

Phase 1
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2020-11-10
Last Posted Date
2020-11-10
Lead Sponsor
MSI Methylation Sciences, Inc.
Target Recruit Count
34
Registration Number
NCT04623034

Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)

Phase 2
Completed
Conditions
Major Depressive Disorder (MDD)
Interventions
Drug: Placebo
First Posted Date
2013-07-31
Last Posted Date
2016-03-18
Lead Sponsor
MSI Methylation Sciences, Inc.
Target Recruit Count
376
Registration Number
NCT01912196
Locations
🇺🇸

MSI Investigational Site, Bellevue, Washington, United States

🇺🇸

MSI INvestigational Site, Kissimmee, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath